Aquestive(AQST) - 2023 Q2 - Earnings Call Presentation

Product Development - Anaphylm pivotal trial protocol submitted to FDA in early August[7] - Company completed additional pilot PK study (AQ109103) for Anaphylm in Q2 2023[7] - Libervant NDA for the two- to five-year-old age group was submitted in Q2[9] Financial Performance - Q2 2023 revenue was $13.2 million, a 24% year-over-year increase compared to Q2 2022 (adjusted for the out-license of Sympazan)[8] - The company ended Q2 2023 with $22.4 million in cash and cash equivalents[8] - Debt was reduced by $3.4 million in Q2 2023, with a year-to-date reduction of $12.5 million[8] Manufacturing - Manufactured 47.9 million doses in June, a 43% increase from Q1 2023[10] Financial Outlook - The company anticipates total revenues of approximately $44 to $48 million for 2023[19] - The company anticipates Non-GAAP adjusted EBITDA loss of approximately $19 to $22 million for 2023[19]